Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8787277 | 0.85 | KMT2A (0.44) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4933046 | 0.84 | TSHR (0.46) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL22286228 | 0.84 | MAPK1 (0.46) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL21974827 | 0.84 | KDM4E (0.42) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4625215 | 0.83 | NPC1 (0.48) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL5212164 | 0.82 | CYP1A2 (0.49) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1865236 | 0.81 | PLAT (0.40) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL20551457 | 0.80 | MAPK1 (0.41) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL23122041 | 0.80 | SMN1; SMN2 (0.40) | KDM4EGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL20551865 | 0.80 | MAPK1 (0.43) | KDM4EGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245472-A1 | COMPOUNDS AND RELATED METHODS USEFUL FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
| EP-1067121-B1 | 5-Aminopyrazole-4-carboxylate derivative and process for preparing the same | MITSUI CHEMICALS INC (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1067121-B1 | 5-Aminopyrazole-4-carboxylate derivative and process for preparing the same | MITSUI CHEMICALS INC (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-6235911-B1 | 5-aminopyrazole-4-carboxylate derivative and process for preparing the same | MITSUI CHEMICALS, INC. (JP) | 2001-05-22 | — | — | US | disclosed |
| JP-2001058982-A | ESTER DERIVATIVE OF 5-AMINOPYRAZOLE-4-CARBOXYLIC ACID AND ITS PRODUCTION | MITSUI CHEMICALS INC | 2001-03-06 | — | — | JP | disclosed |
| EP-1067121-A2 | 5-Aminopyrazole-4-carboxylate derivative and process for preparing the same | Mitsui Chemicals, Inc. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | KDM4E 4117/4885GABRP 1038/4885GABRD 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.